These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22542316)

  • 21. Discovery and application of protein biomarkers for ovarian cancer.
    Gagnon A; Ye B
    Curr Opin Obstet Gynecol; 2008 Feb; 20(1):9-13. PubMed ID: 18196999
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Biospecimen collection, processing, and analysis: new challenges for oncology nurses.
    Neumann RM; Garvey C; Kaufman S
    Semin Oncol Nurs; 2014 May; 30(2):117-23. PubMed ID: 24794085
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.
    Buyse M
    Cancer J; 2009; 15(5):421-5. PubMed ID: 19826362
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Translational crossroads for biomarkers.
    Bast RC; Lilja H; Urban N; Rimm DL; Fritsche H; Gray J; Veltri R; Klee G; Allen A; Kim N; Gutman S; Rubin MA; Hruszkewycz A
    Clin Cancer Res; 2005 Sep; 11(17):6103-8. PubMed ID: 16144908
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Functional genomics and proteomics in the clinical neurosciences: data mining and bioinformatics.
    Phan JH; Quo CF; Wang MD
    Prog Brain Res; 2006; 158():83-108. PubMed ID: 17027692
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mass spectrometry-based clinical proteomics: head-and-neck cancer biomarkers and drug-targets discovery.
    Matta A; Ralhan R; DeSouza LV; Siu KW
    Mass Spectrom Rev; 2010; 29(6):945-61. PubMed ID: 20945361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Proteomics and biomarkers for ovarian cancer diagnosis.
    Zhang B; Barekati Z; Kohler C; Radpour R; Asadollahi R; Holzgreve W; Zhong XY
    Ann Clin Lab Sci; 2010; 40(3):218-25. PubMed ID: 20689132
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Strategies for discovering novel cancer biomarkers through utilization of emerging technologies.
    Kulasingam V; Diamandis EP
    Nat Clin Pract Oncol; 2008 Oct; 5(10):588-99. PubMed ID: 18695711
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum cancer biomarker discovery through analysis of gene expression data sets across multiple tumor and normal tissues.
    Jin H; Lee HC; Park SS; Jeong YS; Kim SY
    J Biomed Inform; 2011 Dec; 44(6):1076-85. PubMed ID: 21872680
    [TBL] [Abstract][Full Text] [Related]  

  • 30. "Omics" data and levels of evidence for biomarker discovery.
    Ghosh D; Poisson LM
    Genomics; 2009 Jan; 93(1):13-6. PubMed ID: 18723089
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomarkers in translational research: focus on discovery, development and translation of protein biomarkers to clinical immunoassays.
    Rai AJ
    Expert Rev Mol Diagn; 2007 Sep; 7(5):545-53. PubMed ID: 17892363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proteomic approaches for serum biomarker discovery in cancer.
    Maurya P; Meleady P; Dowling P; Clynes M
    Anticancer Res; 2007; 27(3A):1247-55. PubMed ID: 17593616
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Conference report and review: current status of biomarkers potentially associated with prostate cancer outcomes.
    Flaig TW; Nordeen SK; Lucia MS; Harrison GS; Glodé LM
    J Urol; 2007 Apr; 177(4):1229-37. PubMed ID: 17382696
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging biomarkers for prostate cancer diagnosis, staging, and prognosis.
    Shariat SF; Scherr DS; Gupta A; Bianco FJ; Karakiewicz PI; Zeltser IS; Samadi DB; Akhavan A
    Arch Esp Urol; 2011 Oct; 64(8):681-94. PubMed ID: 22052751
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical proteomics and biomarker discovery.
    Johann DJ; McGuigan MD; Patel AR; Tomov S; Ross S; Conrads TP; Veenstra TD; Fishman DA; Whiteley GR; Petricoin EF; Liotta LA
    Ann N Y Acad Sci; 2004 Jun; 1022():295-305. PubMed ID: 15251975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The discovery and validation of colorectal cancer biomarkers.
    Ang CS; Phung J; Nice EC
    Biomed Chromatogr; 2011 Jan; 25(1-2):82-99. PubMed ID: 21058408
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Implications of salivary proteomics in drug discovery and development: a focus on cancer drug discovery.
    Hu S; Yen Y; Ann D; Wong DT
    Drug Discov Today; 2007 Nov; 12(21-22):911-6. PubMed ID: 17993408
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An overview of biomarkers for the ovarian cancer diagnosis.
    Zhang B; Cai FF; Zhong XY
    Eur J Obstet Gynecol Reprod Biol; 2011 Oct; 158(2):119-23. PubMed ID: 21632171
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Risk biomarkers and current strategies for cancer chemoprevention.
    Kelloff GJ; Boone CW; Crowell JA; Nayfield SG; Hawk E; Malone WF; Steele VE; Lubet RA; Sigman CC
    J Cell Biochem Suppl; 1996; 25():1-14. PubMed ID: 9027592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A decade of tissue microarrays: progress in the discovery and validation of cancer biomarkers.
    Camp RL; Neumeister V; Rimm DL
    J Clin Oncol; 2008 Dec; 26(34):5630-7. PubMed ID: 18936473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.